- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Immune-related adverse events of immune checkpoint inhibitors
-
- TADANO Hiroki
- Department of Pathology, Sapporo Medical University School of Medicine
-
- TORIGOE Toshihiko
- Department of Pathology, Sapporo Medical University School of Medicine
Bibliographic Information
- Other Title
-
- 免疫チェックポイント阻害剤の免疫性副作用
Search this article
Description
<p> Development and application of anti-CTLA-4 antibody and anti-PD-1 antibody to cancer immunotherapy brought great survival benefits to advanced cancer patients. They have been applied to various cancers such as melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin's disease, and head and neck cancers, and there is no doubt that immunotherapy is becoming a standard therapy as well as surgery, chemotherapy, and radiotherapy. On the other hand, immune-related adverse events (irAEs) have been increasingly reported. Nevertheless, mechanisms of the immune-mediated toxicities are still unclear. There has been a growing interest in the elucidation of the mechanisms. This review describes the general characteristics of irAEs induced by immune checkpoint inhibitors, especially 1. Heterogeneity, 2. Multiplicity, 3. Durability, and 4. Correlativity.</p>
Journal
-
- Japanese Journal of Clinical Immunology
-
Japanese Journal of Clinical Immunology 40 (2), 102-108, 2017
The Japan Society for Clinical Immunology
